With the emergence of dPCR technology and the improvement of detection sensitivity, clinicians can distinguish whether the JAK2 V617F mutation is a hidden subclone within CML or a novel mutation induced by drug pressure. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.